Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.59B |
$31.41
+0.10%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.59B |
$34.70
+0.32%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.57B |
$6.44
+2.55%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.54B |
$41.52
+2.14%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$1.53B |
$27.49
+0.44%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$1.53B |
$3.85
+1.45%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.52B |
$33.77
+1.66%
|
|
VIR
Vir Biotechnology, Inc.
Vir is expanding a targeted oncology portfolio around masked T-cell engagers, placing it in Biotech - Oncology.
|
$1.50B |
$10.76
+4.11%
|
|
ATRC
AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
|
$1.48B |
$29.73
+2.94%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.47B |
$131.44
-0.89%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.44B |
$8.82
+2.14%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$1.41B |
$14.80
+0.99%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.41B |
$3.96
+0.38%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.36B |
$11.18
+2.81%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.35B |
$28.06
+4.43%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$1.32B |
$23.98
+0.21%
|
|
AHG
Akso Health Group
Cancer therapy/oncology biotech focus and planned oncology centers.
|
$1.30B |
$2.33
-0.85%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.29B |
$19.80
+5.91%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.28B |
$88.42
+6.39%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$1.25B |
$7.49
+2.32%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$1.25B |
$16.72
+11.17%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.24B |
$14.96
+1.01%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$1.22B |
$29.73
+0.41%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.20B |
$4.00
+4.57%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.18B |
$17.54
+1.21%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$1.18B |
$18.32
+2.98%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.17B |
$21.82
+0.25%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.17B |
$26.07
+4.32%
|
|
BHVN
Biohaven Ltd.
OCD and other neuropsychiatric indications (e.g., MDD) place Biohaven in Neuropsychiatric Drug Development.
|
$1.16B |
$10.97
+9.59%
|
Showing page 8 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
